Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
L-DOPA for PTSD Therapeutic Learning
NCT04558112Phase 2Unknown
- Sponsor
- University of Wisconsin–Madison
- Start
- Feb 2021
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in post-traumatic stress disorder (PTSD) comparing 100 mg L-DOPA with Placebo (2 arms). Primary endpoint: Change in negative emotional responding to trauma scripts at Day 2. Status: unknown.
02
Drugs
levodopa
03
Conditions
post-traumatic stress disorder (PTSD)
Beyond the preview
Go deeper on NCT04558112.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04558112.